AAV's golden jubilee

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 807-808

  Muzyczka, Nicholas ^a   Berns, Kenneth I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA HELICASE; PARVOVIRUS VECTOR; CD4 ANTIGEN; IMMUNOGLOBULIN;

ADENO ASSOCIATED VIRUS; BACULOVIRIDAE; CRYSTAL STRUCTURE; DNA REPLICATION; DNA SEQUENCE; GENE EXPRESSION REGULATION; HELPER VIRUS; HERPESVIRIDAE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INVERTED TERMINAL REPEAT; NONHUMAN; NOTE; OPEN READING FRAME; REP GENE; TISSUE SPECIFICITY; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS PARTICLE; VIRUS STRAIN; ANIMAL; DEPENDOPARVOVIRUS; FEMALE; GENETICS; IMMUNOLOGY; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS ENTRY;

ANIMALS; ANTIGENS, CD4; DEPENDOVIRUS; FEMALE; IMMUNOGLOBULINS; MALE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INTERNALIZATION;

EID: 84928956254     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.55     Document Type: Note

References (27)

1. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, et al. (2015). AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519: 87-91
2. Atchison RW, Casto BC and Hammon W. (1965). Adenovirus-associated defective virus particles. Science 149: 754-756
3. Samulski RJ, Berns KI, Tan M and Muzyczka N. (1982). Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 79: 2077-2081
4. Srivastava A, Lusby EW and Berns KI. (1983). Nucleotide sequence and organization of the adenoassociated virus 2 genome. J Virol 45: 555-564
5. Hauswirth WW and Berns KI. (1977). Origin and termination of adeno-associated virus DNA replication. Virology 78: 488-499
6. Hermonat PL and Muzyczka N. (1984). Use of adenoassociated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 81: 6466-6470
7. McLaughlin SK, Collis P, Hermonat PL and Muzyczka N. (1988). Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 62: 1963-1973
8. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, et al. (1990). Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215
9. Samulski RJ and Muzyczka N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1: 427-451
10. Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, et al. (1996). In vivo model of adeno-associated virus vector persistence and rescue. J Virol 70: 3235-3241
11. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L and Kay MA. (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75: 6969-6976
12. Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, et al. (1996). A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Human Gene Ther 7: 1145-1159
13. Boye SE, Boye SL, Lewin AS and Hauswirth WW. (2013). A comprehensive review of retinal gene therapy. Mol Ther 21: 509-519
14. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365
15. Yla-Herttuala S. (2012). Endgame: Glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol Ther 20: 1831-1832
16. Agbandje-McKenna M and Kleinschmidt J. (2011). AAV capsid structure and cell interactions. Methods Mol Biol 807: 47-92
17. Gao G, Vandenberghe LH and Wilson JM. (2005). New recombinant serotypes of AAV vectors. Curr Gene Ther 5: 285-297
18. Kotterman MA and Schaffer DV. (2014). Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 15: 445-451
19. Xiao X, Li, J and Samulski RJ. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232
20. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5: 938-945
21. Grimm D, Kern A, Rittner K and Kleinschmidt JA. (1998). Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 9: 2745-2760
22. Conway JE, Zolotukhin S, Muzyczka N, Hayward GS and Byrne BJ. (1997). Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap. J Virol 71: 8780-8789
23. Smith RH, Levy JR and Kotin RM. (2009). A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 17: 1888-1896
24. Nash K, Chen W and Muzyczka N. (2008). Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins. J Virol 82: 1458-1464
25. Sonntag F, Schmidt K and Kleinschmidt JA. (2010). A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci USA 107: 10220-10225
26. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ and Bjorklund A. (2003). Nigrostriatal alphasynucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci USA 100: 2884-2889
27. Fenno L, Yizhar O and Deisseroth K. (2011). The development and application of optogenetics. Annu Rev Neurosci 34: 389-412